Healthcare provider profile · identity verified

Peter A. Javaheri, MD

Internal Medicine · ROSEVILLE, CA · NPI 1023196789

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	369	136
Amlodipine Besylate	Amlodipine Besylate	236	86
Levothyroxine Sodium	Levothyroxine Sodium	182	73
Atenolol	Atenolol	163	54
Furosemide	Furosemide	132	52
Lisinopril	Lisinopril	126	48
Losartan Potassium	Losartan Potassium	120	49
Albuterol Sulfate Hfa	Albuterol Sulfate	119	52
Ibuprofen	Ibuprofen	104	44
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	94	36
Trazodone Hcl	Trazodone Hcl	94	32
Metoprolol Tartrate	Metoprolol Tartrate	91	29
Omeprazole	Omeprazole	82	32
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	78	39
Tamsulosin Hcl	Tamsulosin Hcl	78	35
Fluticasone Propionate	Fluticasone Propionate	75	33
Famotidine	Famotidine	73	27
Potassium Chloride	Potassium Chloride	69	25
Metformin Hcl Er	Metformin Hcl	68	28
Alendronate Sodium	Alendronate Sodium	67	29
Tizanidine Hcl	Tizanidine Hcl	65	18
Alvesco	Ciclesonide	63	19
Gabapentin	Gabapentin	63	27
Allopurinol	Allopurinol	48	19
Terazosin Hcl	Terazosin Hcl	42	13
Metoprolol Succinate	Metoprolol Succinate	41	22
Pantoprazole Sodium	Pantoprazole Sodium	40	21
Prednisone	Prednisone	38	20
Rosuvastatin Calcium	Rosuvastatin Calcium	38	17
Sertraline Hcl	Sertraline Hcl	38	14
Spironolactone	Spironolactone	38	15
Triamcinolone Acetonide	Triamcinolone Acetonide	37	22
Bupropion Xl	Bupropion Hcl	36	11
Hydrochlorothiazide	Hydrochlorothiazide	34	19
Venlafaxine Hcl Er	Venlafaxine Hcl	34	11
Azelastine Hcl	Azelastine Hcl	32	suppressed
Humulin N	Insulin Nph Human Isophane	31	12
Lovastatin	Lovastatin	31	11
Meloxicam	Meloxicam	31	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	31	15
Simvastatin	Simvastatin	31	17
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	31	suppressed
Ondansetron Odt	Ondansetron	30	suppressed
Spiriva Respimat	Tiotropium Bromide	29	13
Tramadol Hcl	Tramadol Hcl	28	14
Fluocinonide	Fluocinonide	27	suppressed
Humulin R	Insulin Regular, Human	27	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	27	18
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	24	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	23	12
Montelukast Sodium	Montelukast Sodium	23	suppressed
Clopidogrel	Clopidogrel Bisulfate	22	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	20	11
Metformin Hcl	Metformin Hcl	20	suppressed
Ondansetron Hcl	Ondansetron Hcl	20	suppressed
Buspirone Hcl	Buspirone Hcl	19	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	19	suppressed
Glipizide	Glipizide	19	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	19	suppressed
Eliquis	Apixaban	18	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	18	suppressed
Jardiance	Empagliflozin	17	suppressed
Acyclovir	Acyclovir	16	suppressed
Duloxetine Hcl	Duloxetine Hcl	16	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	16	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	16	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	15	15
Naproxen	Naproxen	15	suppressed
Amoxicillin	Amoxicillin	14	suppressed
Cefadroxil	Cefadroxil	14	12
Ipratropium Bromide	Ipratropium Bromide	14	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	14	suppressed
Warfarin Sodium	Warfarin Sodium	14	suppressed
Carvedilol	Carvedilol	13	suppressed
Ciclopirox	Ciclopirox	13	suppressed
Colchicine	Colchicine	13	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Levetiracetam	Levetiracetam	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Finasteride	Finasteride	12	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	12	suppressed
Divalproex Sodium	Divalproex Sodium	11	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	11	suppressed
Rizatriptan	Rizatriptan Benzoate	11	suppressed
Trospium Chloride	Trospium Chloride	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error